Brief: Lidds To Cease Development Of Nanodotax, Nanoimod, And NOV 202
02/04/2025 14:04
April 2 (Reuters) - Lidds AB LIDDS.ST: TO CEASE DEVELOPMENT OF NANODOTAX, NANOIMOD, AND NOV 202 DOES NOT HAVE THE OPPORTUNITY TO FURTHER CAPITALIZE THE COMPANY FOR CLINICAL STUDIES TO FOUCUS ON PRESERVING THE VALUES THAT THE COMPANY Source text: ID:nMFN5SCzGB Further company coverage: LIDDS.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Lidds AB
See all newsBrief: Liquidator To Apply For Lidds To Be Declared Bankrupt
Brief: Lidds To Delist Shares From Nasdaq First North
Brief: Lidds Proposes Voluntary Liquidation And Delisting
Brief: Lidds Decides To Terminate Process Regarding Reverse Acquisition Of Proport Invest
Brief: Lidds Signs Agreement For Reverse Takeover Of Proport Invest